A retrospective medical database analysis of T2D patients (n = 39,275) treated with exenatide or other glucose-lowering therapies (n = 381,218) indicated that the GLP-1 agonist might reduce in 19% the incidence of MACCE and in 12% cardiovascular hospitalizations [71]
Experimental oxygen-delivery/metabolic performance compound tracked in research circles
In musculoskeletal research, BPC-157 has been examined in models involving tendons, ligaments, skeletal muscle, and connective tissues
Many users report feeling the effects of alcohol faster and more intensely
Quality Pledge: Made in an FSSAI inspected facility to meet the stringent standards of US Pharmacopeia (USP) for quality, purity, potency and disintegration
East Asia: In East Asia, China and Japan are experiencing strong demand for GLP-1 receptor agonists, driven by an increasing prevalence of type 2 diabetes and expanding access to diabetes treatments